Drug Discovery World

JUNE 14, 2023

After reviewing results of the DESTINY-Breast04 trial and other studies, the CAP/ASCO panel determined that the current HER2 testing recommendations remain valid to identify all breast cancer patients who might benefit from the full spectrum of HER2 related therapies.

Protein Expression 130

Protein Expression Clinical Trials Trials Laboratories 130

ASPET

JUNE 27, 2024

Estrogen receptor (ER)-negative breast cancers are known to be aggressive and unresponsive to anti-estrogen therapy, and triple negative breast cancers are associated with poor prognosis and metastasis. Thus, new targeted therapies are needed.

Therapies 40

Therapies Protein Expression 40

Advarra

JANUARY 11, 2024

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

Chemical Biology and Drug Design

AUGUST 2, 2023

Linagliptin administered to the type 1 diabetic mouse heart significantly reduced the expression levels of the total and cleaved forms of ATF6, ATF4, and p-JNK, caspase 3. According to ELISA findings, TUDCA was more effective in reducing NOX 1 and MDA levels than linagliptin.

Protein Expression 100

Protein Expression Therapies Treatment Research 100

Chemical Biology and Drug Design

MARCH 5, 2024

In addition, western blot analysis showed that CA-COS inhibits the protein expression of iNOS and nuclear factor kappa B (NF-kB), including p50 and p65, and mitogen-activated protein kinase (MAPK) signaling pathways.

Protein Expression 100

Protein Expression Therapies Production Disease 100

Drug Discovery World

SEPTEMBER 8, 2022

Pleco claims that its novel Plecoid therapies have the potential to positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell, thereby improving the effectiveness of existing chemotherapy.

Protein Expression 130

Protein Expression Drugs Government FDA 130

ASPET

OCTOBER 20, 2023

We previously showed that epigenetic histone dysregulations were associated with decreased Brain Derived Neurotrophic Factor (BDNF) expression in a GWI rat model. GWI has no effective therapies. Ketamine (KET) has recently been approved by the FDA for therapy-resistant depression. mg/kg s.c.,

Protein Expression 40

Protein Expression Clinical Trials Therapies FDA 40

Drug Discovery World

SEPTEMBER 13, 2023

The authors conclude that this now well-defined subgroup of “inflammatory psychoses” calls for the development of a differential therapeutic approach in psychoses and, more specifically, the identification and development of further HERV-related precision medicine therapies.

Protein Expression 130

Protein Expression Clinical Trials Hospitals Trials 130

The Pharma Data

MARCH 30, 2021

Broad expression of FAP demonstrated in tumors or in tumor stroma across many solid tumors 1 ,2 ,3. Novartis Oncology continues to reimagine cancer care through development of robust radioligand therapy portfolio. We continue to invest in radioligand therapy as one of the four unique platforms of Novartis Oncology.

Licensing 52

Licensing Licensing Therapies Protein Expression 52

The Pharma Data

APRIL 27, 2022

Based on DESTINY-Breast04 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a significant improvement in both progression-free survival and overall survival Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers.

Therapies 52

Therapies Trials Protein Expression Treatment 52

Drug Discovery World

APRIL 17, 2024

Increasing gene expression via protein replacement or gene therapy has been shown to have limitations and drawbacks. CAMP4 is the only company modulating gene expression at the transcriptional level to increase mRNA production and thereby increase healthy protein production. Can you give some examples?

Science 147

Science RNA Disease Protein Expression 147

Drug Target Review

OCTOBER 6, 2023

This interview explores how CoRegen’s innovative techniques are not only transforming cancer treatment but also hold promise for a wide range of medical applications, all while minimising the side effects often associated with traditional therapies. What are the key benefits of your approach?

Small Molecule 110

Small Molecule Engineering Protein Expression Regulations 110

The Pharma Data

JANUARY 16, 2021

Etta Biotech”), to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotech’s transient transfection high titer protein expression platform. About JS Bio.

Protein Expression 52

Protein Expression Protein Production Production Drug Development 52

PPD

OCTOBER 12, 2023

Cell and gene therapies (CGTs) are one of the fastest growing areas in human therapeutics. These treatments use a vector to introduce the desired nucleic acid code to replace or modify protein expression or use cells to alter/restore a specific cell type.

Laboratories 52

Laboratories Protein Expression Clinical Trials Pharmacokinetics 52

Drug Discovery World

APRIL 30, 2024

Reece Armstrong explores the potential and future opportunities for mRNA-based therapies. For instance, consider how at the end of 2018, the mRNA therapies market was valued at $3.43 mRNA-based approaches can produce proteins / peptides by using protein synthesis which is processed in a transfected cell 1.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

Broad Institute

JUNE 27, 2024

Science (2024) Related content New gene delivery vehicle shows promise for human brain gene therapy My Quest to Cure Prion Disease — Before It’s Too Late | Sonia Vallabh | TED Prion diseases lead to rapid neurodegeneration and death and are caused by misshapen versions of the prion protein in the brain. “As

Disease 142

Disease Therapies Engineering Clinical Trials 142

Drug Target Review

FEBRUARY 19, 2024

A pivotal moment for me was when I realised that if I understood disease mechanisms on a molecular level, I could be part of an industry that helps develop medicines/therapies for those who need them most. I loved learning how to explain at the molecular level what was happening in nature, in human beings and disease settings.

Molecular Biology 109

Molecular Biology Science Protein Expression Production 109

Drug Target Review

MARCH 15, 2024

As discussed above, recent advances in gene editing tools and transposon-based vectors have facilitated targeted and consistent cell line engineering for the development of protein expressing CHO cell lines. Cell Gene Therapy Insights 2017; 3(2), 131-158, 10.18609/cgti.2017.014. Biotechnol Prog. 2017 Nov;33(6):1468-1475.

Engineering 104

Engineering Molecular Biology Protein Expression Medical Schools 104

The Pharma Data

JUNE 7, 2023

3,4,5 TROP2 is a protein expressed in more than 90% of NSCLC tumors. Rahway, NJ, USA), an anti-PD-1 therapy. 3,4,5 TROP2 is a protein expressed in more than 90% of NSCLC tumors. Rahway, NJ, USA), an anti-PD-1 therapy. More than one million people are diagnosed with NSCLC at an advanced stage each year.

Trials 40

Trials Protein Expression Therapies Treatment 40

The Pharma Data

MAY 2, 2022

The target of DF7001 is 5T4, a protein expressed on cancer cells and stromal cells that support tumor growth associated with poor prognosis in several cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, breast cancer, and head and neck squamous cell carcinomas (HNSCC). View the full release here: [link].

Licensing 52

Licensing Licensing Research Protein Expression 52

The Pharma Data

SEPTEMBER 28, 2021

The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA) from birth to 6 weeks aged and data supporting the continued clinical investigation of gene therapy, SRP-9001, in Duchenne dystrophy (DMD).

Clinical Trials 52

Clinical Trials Protein Expression FDA Therapies 52

The Pharma Data

JANUARY 10, 2021

FBX-101 is a first-in-human AAV gene therapy. Harpoon Therapeutics dosed the first patient with HPN328 in its Phase I/II trial of small cell lung cancer (SCLC) and other tumors associated with DLL3 expression. The study hit the mark on its primary biological endpoint of micro-dystrophin protein expression.

Clinical Trials 52

Clinical Trials Trials FDA Protein Expression 52

The Pharma Data

DECEMBER 8, 2020

Since partnering with Eli Lilly to produce the first monoclonal antibody therapy approved for mild-to-moderate COVID-19 patients, antibody discovery company AbCellera is going big on the Nasdaq. BioAge is on the cusp of taking pilot therapies BGE-117 and BGE-175 into clinical trials, targeting the first half of 2021.

RNA 52

RNA Protein Expression Therapies Disease 52

The Pharma Data

AUGUST 16, 2021

The vaccine candidate, presently at a preclinical development stage, is a non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles (LNPs). CureVac had its initial public offering on the New York Nasdaq in August 2020.

Immune Response 52

Immune Response Vaccine Virus RNA 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Debets will present: ‘Selection and validation of TCR-like antibodies and TCRs for adoptive therapy’. from engineered peptide and antibody libraries’.

Engineering 162

Engineering Protein Expression Therapies Science 162

Drug Target Review

SEPTEMBER 4, 2023

10 Reported cAMP as the second messenger signalling molecule conserved from bacteria to humans and modulates several biological processes, including protein expression, gene transcription, and cell development and differentiation.

Drugs 110

Drugs RNA DNA Disease 110

The Pharma Data

APRIL 26, 2022

This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

Drug Discovery World

SEPTEMBER 5, 2022

The success of targeted therapies in cancer comes on the heels of identifying specific molecular targets resulting from genetic variations. Modulations in protein expression levels or the presence of dysfunctional proteins observed in individuals with specific mutations act as biomarkers in selecting patients for targeted therapies. .

Drug Development 130

Drug Development Protein Expression Drugs Therapies 130

Drug Discovery World

JANUARY 23, 2023

Our initial focus is to develop mRNA therapies that act through multiple immune mediated mechanisms to deliver potentially curative treatments in oncology. In solid tumours, Strand’s mRNA approach has the potential to significantly improve response rates to checkpoint inhibitor therapy. DS: What will 2023 hold for your company?

RNA 246

RNA Engineering Therapies Disease 246

The Pharma Data

JULY 21, 2021

This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi , the bacteria that cause Lyme disease. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Vaccine 52

Vaccine Disease Trials Protein Expression 52

The Pharma Data

JANUARY 15, 2021

Enhertu previously received Priority Review and Breakthrough Therapy Designation (BTD) in the U.S. 3 HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of many types of tumors including breast, gastric, lung and colorectal cancer. Targeted Therapies for Stomach Cancer. 2,5 In the U.S.,

Treatment 52

Treatment Trials Disease Therapies 52

The Pharma Data

JANUARY 13, 2021

Dr. Lederman continued, “Despite the recognized promise of anti-CD40-ligand mAb therapy, first generation anti-CD40-ligand mAbs were limited because their crystallizable fragment (Fc) domain interacted with a cell surface receptor called Fc?RII, RII, which resulted in an increased risk of thrombosis. International Immunol. (11):1583

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

Drug Discovery World

NOVEMBER 30, 2023

This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It It was by Nicholas Field, Principal Scientist, Purification Development, Lonza, titled: ‘Tailored CMC solutions to overcome the challenges in bispecific, Fab and Fc-fusion protein development programs’.

Protein Expression 147

Protein Expression Engineering DNA Therapies 147

The Anticancer Fund

SEPTEMBER 29, 2021

Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial Published in JAMA Oncology This large (n=2639) trial of adjuvant celecoxib vs. placebo in women with HER2-negative primary breast cancer finds no effect on disease free survival at 10-years follow up.

Clinical Trials 40

Clinical Trials Drugs Trials Protein Expression 40

Conversations in Drug Development Trends

MAY 30, 2024

This research community is exploring diverse therapeutic avenues and creative thinking, including gene therapies, cell therapies, immunotherapies, novel drug candidates, and the repurposing of drugs from other indications.

Treatment 81

Treatment Small Molecule Clinical Trials Therapies 81

Drug Discovery World

FEBRUARY 28, 2023

With only 10% of these conditions indicated for an approved therapy, there is a sizable opportunity for scientists and companies to develop treatments for patients with no other options to turn to. Therefore, the risk for off-target insertional mutagenesis is greatly reduced.

Disease 130

Disease Treatment Vaccine DNA 130

Drug Discovery World

MAY 2, 2023

These modifications lead to alterations in the function of the proteins expressed by these genes, manifesting in cellular processes dependent on those proteins. This indicates that an efficient anti-cancer therapy must inhibit the activity of the proteins expressed by these genes.

DNA 130

DNA RNA Protein Expression Drugs 130